• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

One Size Doesn't Fit All: Revisiting the Threshold, Target, and Type of Erythropoietin-Stimulating Agent Therapy in Anemia of CKD.

作者信息

Prasad Pallavi, Yamagata Kunihiro

机构信息

Department of Nephrology, Vardhman Mahavir Medical College and Safdarjung Hospital New Delhi, India.

Department of Nephrology, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.

出版信息

Kidney Int Rep. 2024 May 25;9(7):1954-1956. doi: 10.1016/j.ekir.2024.05.023. eCollection 2024 Jul.

DOI:10.1016/j.ekir.2024.05.023
PMID:39081729
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11284411/
Abstract
摘要

相似文献

1
One Size Doesn't Fit All: Revisiting the Threshold, Target, and Type of Erythropoietin-Stimulating Agent Therapy in Anemia of CKD.一刀切并不适用于所有情况：重新审视慢性肾脏病贫血中促红细胞生成素刺激剂治疗的阈值、目标和类型
Kidney Int Rep. 2024 May 25;9(7):1954-1956. doi: 10.1016/j.ekir.2024.05.023. eCollection 2024 Jul.
2
Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.甲氧基聚乙二醇-促红细胞生成素β作为一种新型促红细胞生成刺激剂，对非透析慢性肾脏病患者可能具有肾脏保护和心血管保护作用。
Curr Pharm Biotechnol. 2017;18(4):303-308. doi: 10.2174/1389201018666170127104801.
3
A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.一项关于己酮可可碱治疗 CKD 贫血患者促红细胞生成素刺激剂低反应性的随机、安慰剂对照试验：用己酮可可碱处理促红细胞生成素抵抗（HERO）试验。
Am J Kidney Dis. 2015 Jan;65(1):49-57. doi: 10.1053/j.ajkd.2014.06.020. Epub 2014 Aug 10.
4
Home Therapy to Reduce Office Visits for Patients with Chronic Kidney Disease and Anemia.家庭治疗以减少慢性肾病和贫血患者的门诊就诊次数。
Nephrol Nurs J. 2017 Jan-Feb;44(1):29-33.
5
Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.皮下注射 C.E.R.A. 用于维持治疗儿科慢性肾脏病贫血患者的 2 期、开放标签、单臂、多中心研究。
Am J Kidney Dis. 2023 Jun;81(6):684-694.e1. doi: 10.1053/j.ajkd.2022.11.006. Epub 2022 Dec 29.
6
Effects of Erythropoietin-Stimulating Agents on Blood Pressure in Patients with Non-Dialysis CKD and Renal Anemia.促红细胞生成素刺激剂对非透析慢性肾脏病合并肾性贫血患者血压的影响
Kidney Dis (Basel). 2020 Jul;6(4):299-308. doi: 10.1159/000507396. Epub 2020 Jun 12.
7
Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan database.使用美国一个大型医疗计划数据库，对促红细胞生成素刺激剂在非透析依赖型慢性肾脏病患者中于促红细胞生成素（阿法依泊汀）治疗降低心血管事件试验（TREAT）前后的使用情况进行研究。
Am J Kidney Dis. 2014 Nov;64(5):706-13. doi: 10.1053/j.ajkd.2014.05.013. Epub 2014 Jul 8.
8
An Overview of Safety and Efficacy Between Hypoxia-Inducible Factor-Prolyl-Hydroxylase Inhibitors and Erythropoietin-Stimulating Agents in Treating Anemia in Chronic Kidney Disease Patients.缺氧诱导因子脯氨酰羟化酶抑制剂与促红细胞生成素刺激剂在治疗慢性肾脏病患者贫血方面的安全性和有效性概述
Cureus. 2023 Jul 17;15(7):e42045. doi: 10.7759/cureus.42045. eCollection 2023 Jul.
9
Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review.甲氧基聚乙二醇-促红细胞生成素β与阿法达贝泊汀治疗非透析依赖型慢性肾脏病贫血的系统评价
Int J Clin Pharm. 2014 Dec;36(6):1115-25. doi: 10.1007/s11096-014-0023-x. Epub 2014 Oct 7.
10
Erythropoietin-stimulating agent-resistant vitamin B deficiency anemia in a pediatric patient on hemodialysis.一名接受血液透析的儿科患者中对促红细胞生成素刺激剂耐药的维生素B缺乏性贫血
Pediatr Nephrol. 2021 Feb;36(2):473-476. doi: 10.1007/s00467-020-04810-1. Epub 2020 Nov 6.

本文引用的文献

1
Iron Metabolism in Cardiovascular Disease: Physiology, Mechanisms, and Therapeutic Targets.铁代谢与心血管疾病：生理、机制与治疗靶点。
Circ Res. 2023 Feb 3;132(3):379-396. doi: 10.1161/CIRCRESAHA.122.321667. Epub 2023 Feb 2.
2
Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial.阿法达贝泊汀在非糖尿病的晚期 CKD 患者中的应用：一项随机对照试验。
Clin J Am Soc Nephrol. 2020 May 7;15(5):608-615. doi: 10.2215/CJN.08900719. Epub 2020 Apr 3.
3
The influence of the pleiotropic action of erythropoietin and its derivatives on nephroprotection.
促红细胞生成素及其衍生物的多效作用对肾脏保护的影响。
Med Sci Monit. 2013 Jul 22;19:599-605. doi: 10.12659/MSM.889023.
4
High target hemoglobin with erythropoiesis-stimulating agents has advantages in the renal function of non-dialysis chronic kidney disease patients.对于非透析慢性肾病患者，使用促红细胞生成素达到高目标血红蛋白水平对其肾功能具有益处。
Ther Apher Dial. 2012 Dec;16(6):529-40. doi: 10.1111/j.1744-9987.2012.01082.x. Epub 2012 Jun 19.
5
Role of oxidative stress in cardiovascular effects of anemia treatment with erythropoietin in predialysis patients with chronic kidney disease.氧化应激在慢性肾脏病透析前患者促红细胞生成素治疗贫血的心血管效应中的作用
Clin Nephrol. 2012 Mar;77(3):171-81. doi: 10.5414/cn107309.
6
Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury.促红细胞生成素在缺血再灌注损伤实验模型中可改善左心室功能和冠状动脉血流。
Eur J Heart Fail. 2004 Dec;6(7):853-9. doi: 10.1016/j.ejheart.2004.03.012.
7
Left ventricular alterations and end-stage renal disease.左心室改变与终末期肾病
Nephrol Dial Transplant. 2002;17 Suppl 1:29-36. doi: 10.1093/ndt/17.suppl_1.29.